Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299372 | 0.87 | KMT2A (0.68) | MAPTTDP1KMT2AGAACA9 | |
| SCHEMBL6763715 | 0.85 | CA9 (0.61) | MAPTTDP1KMT2AGAACA9 | |
| SCHEMBL20788430 | 0.84 | KMT2A (0.51) | MAPTTDP1L3MBTL1KMT2AGAA | |
| SCHEMBL18017546 | 0.83 | KMT2A (0.57) | MAPTTDP1KMT2AGAACA9 | |
| SCHEMBL20788339 | 0.83 | KMT2A (0.50) | MAPTTDP1L3MBTL1KMT2AGAA | |
| SCHEMBL18865628 | 0.83 | CA9 (0.50) | MAPTKMT2AGAACA9TP53 | |
| SCHEMBL21350911 | 0.81 | KMT2A (0.57) | MAPTTDP1KMT2AGAACA9 | |
| SCHEMBL5363238 | 0.81 | SMN1; SMN2 (0.49) | MAPTTDP1L3MBTL1KMT2AGAA | |
| SCHEMBL5676831 | 0.80 | CHRNA7 (0.61) | MAPTKMT2AGAACA9TP53 | |
| SCHEMBL5340205 | 0.80 | CHRNA7 (0.61) | MAPTTDP1L3MBTL1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3681883-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094278-A | Diphenyl derivatives and their use | 诺华股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| WO-2019053090-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | MAPT 2084/4885TDP1 220/4885L3MBTL1 1366/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | MAPT 2084/4885TDP1 220/4885L3MBTL1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.